Morning Overview on MSN
New prostate cancer immunotherapy slashes biomarkers by up to 99%
An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...
"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.
Watchdog finds failings in prostate cancer treatment in North Wales going back almost a decade.
They use the body's own immune system to detect and kill cancer cells "Immunotherapies have been very promising and has ...
Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who ...
From AI-generated biopsy reports to new imaging techniques, these are the latest developments in advanced prostate cancer research that your doctor may be keeping tabs on. Much of managing advanced ...
Prostate cancer diagnoses increased by 3% per year from 2014 to 2021, with the sharpest increase seen in advanced-stage disease. Prostate cancer mortality rates have continued to decline, but at a ...
AUSTIN (KXAN) — More people have been diagnosed with prostate cancer following years of decline. In a recent annual report from the American Cancer Society, it said that the statistics for prostate ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...
Learn the key warning signs of prostate cancer that men often overlook. Early awareness can make all the difference.
Morning Overview on MSN
New prostate cancer immunotherapy cuts biomarkers by up to 99% in trial
A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results